

A randomized double blind placebo controlled study to evaluate the modulation of cognitive functions in Parkinson's subjects by sildenafil

Submission date 30/08/2005	Recruitment status No longer recruiting	☐ Prospectively registered
Registration date 26/09/2005	Overall study status Completed	☐ Protocol
Last Edited 23/05/2016	Condition category Nervous System Diseases	☐ Statistical analysis plan
		☐ Results
		☐ Individual participant data
		☐ Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr David Burn

Contact details

Regional Neurosciences Centre
Newcastle General Hospital
Westgate Road
Newcastle
United Kingdom
NE46BE
+44 (0)1912563425
d.j.burn@ncl.ac.uk

Additional identifiers

Protocol serial number

A1481189

Study information

Scientific Title

A randomized double blind placebo controlled study to evaluate the modulation of cognitive functions in Parkinson's subjects by sildenafil

Acronym

SCOPE

Study objectives

That 48 weeks of sildenafil therapy will stabilize or slow down the progression of cognitive impairment in Parkinson's disease subjects with mild cognitive impairment when compared with untreated Parkinson's disease controls. The study will also assess the effects of sildenafil upon motor state and olfaction in Parkinson's disease since these parameters may also be improved by sildenafil.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Parkinson's disease (PD)

Interventions

Sildenafil dosing in the treatment group will start at 50 mg once daily for 4 weeks. Dosing is then increased to 100 mg daily for a further 44 weeks. The control group will receive matching placebo treatment for 48 weeks.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Sildenafil

Primary outcome(s)

1. To test if 48 weeks of sildenafil therapy will result in improved cognitive functions in Parkinson's disease subjects as measured by the paired association learning (PAL) test
2. To test if 48 weeks of sildenafil therapy will result in improved olfaction in Parkinson's disease subjects as measured by the UPSIT test

Key secondary outcome(s)

To test if 48 weeks of sildenafil therapy will result in improved motor and cognitive function in Parkinson's disease subjects as measured by the Unified Parkinson's Disease Rating Scale (UPDRS), Dyskinesia Rating Scale, Spatial Working Memory Test and Reaction Time Test.

Completion date

30/09/2006

Eligibility**Key inclusion criteria**

1. Male or female subjects (excluding women of child bearing potential) between the ages of 50 and 80 years, inclusive
2. Diagnosis of Parkinson's disease according to UK Parkinson's Disease Society Brain Bank Criteria
3. Diagnosis of Parkinson's disease >12 months
4. Mild cognitive impairment insufficient to fulfill Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for dementia, with MMSE score 18-27
5. University of Pennsylvania Smell Identification Test (UPSIT) test score of <30
6. Subjects must be willing and able to provide written informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

50 Years

Upper age limit

80 Years

Sex

All

Key exclusion criteria

1. Subjects with evidence of severe or unstable concomitant medical illness
2. Known hypersensitivity to, or current use of sildenafil, or other PDE5 inhibitors
3. Clinically significant orthostatic hypotension (defined as disabling postural light-headedness or syncopal episodes associated with a fall in systolic blood pressure on standing of over 30 mmHg)
4. Patient taking anti-psychotic or cholinesterase inhibitor medication
5. Patient taking dopamine agonists
6. Major depressive disorder
7. Anosmia secondary to head injury/non-PD related cause
8. Exclusion of patients with Multiple Systems Atrophy

9. Exclusion of patients with colour-blindness
10. Subjects who were prescribed and/or are taking nitrates or nitric oxide donors in any form (oral, sub-lingual, transdermal, inhalation, aerosols), alpha blockers and/or class IA or III anti-arrhythmic medication
11. Use of medication known or suspected to be potent or moderate inhibitors of cytochrome P4503A4 (excluding ketoconazole, itraconazole, cimetidine, ritonavir)
12. Subjects with congenital QT prolongation
13. Electrocardiogram (ECG) evidence of severe life-threatening rhythm or ischaemic disturbances including acute myocardial infarction (within last year), left bundle branch block, or ventricular tachycardia
14. QTcF prolongation >500 msec
15. Sustained hypertension >170 mmHg systolic or >110 mmHg diastolic; sustained hypotension <90 mmHg systolic or <50 mmHg diastolic
16. History of regular alcohol abuse within 6 months of screening
17. Treatment with investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication

Date of first enrolment

14/12/2004

Date of final enrolment

30/09/2006

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Regional Neurosciences Centre

Newcastle

United Kingdom

NE46BE

Sponsor information

Organisation

Pfizer Inc. (USA)

ROR

<https://ror.org/01xdqrp08>

Funder(s)

Funder type

Industry

Funder Name

Study is fully funded by Pfizer Inc. (USA)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration